Does Dr. KARI BABINSKI have financial conflicts of interest?

Dr. KARI BABINSKI (M.D.) has received a total of $336 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $336 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. KARI BABINSKI?

According to CMS Open Payments data, Dr. KARI BABINSKI received funding from ZIMMER BIOMET HOLDINGS ($287), DEPUY SYNTHES SALES ($38), and FERRING PHARMACEUTICALS ($12).

Does Dr. KARI BABINSKI receive research grants or speaking fees?

Dr. KARI BABINSKI has received $336 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. KARI BABINSKI

M.D.Real-Time Hydrated

Specialty: Orthopaedic Surgery, Sports Medicine

Practice Location: ALBUQUERQUE, NM 87106

NPI Number: 1063490589

LIFETIME INDUSTRY VALUE

$336

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. BABINSKI is a verified Orthopaedic Surgery, Sports Medicine practitioner based in ALBUQUERQUE, NM.

Between 2021 and 2025, Dr. BABINSKI had an overall industry promotional and research financial footprint of $336 as recorded in the federal CMS Open Payments database.

$336 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. BABINSKI's primary funding source is ZIMMER BIOMET HOLDINGS, which accounts for $287 (representing 85.3% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

ZIMMER BIOMET HOLDINGS

Rank 1

$287

85.3%

DEPUY SYNTHES SALES

Rank 2

$38

11.2%

FERRING PHARMACEUTICALS

Rank 3

$12

3.5%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.